In a significant advance for the early and accurate detection of neurodegenerative disorders such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)researchers have developed a skin biopsy test that identifies an abnormal form of alpha-synuclein, known as P-SYN, with an unprecedented 95.5% accuracy.
This scientific milestone, highlighted by the study carried out in multiple centers and of a blind nature, offers new hope for the estimated 200,000 people in the United States who face diagnoses related to synucleinopathies every year.
The findings of this study, led by Dr. Christopher Gibbons of Harvard Medical School, promise not only to improve the early identification of these diseases, but also to accelerate the development of effective drug therapies.
Synucleinopathies, including PD, DLB, multiple system atrophy (MSA), and pure autonomic failure (PAF), represent a clinical challenge due to their variable progression and overlap of symptoms between different disorders.
The lack of reliable biomarkers has historically made accurate and timely diagnosis difficult, leaving many patients without clear answers for prolonged periods.
skin biopsy
The skin biopsy test developed in this study represents an innovative solution and minimally invasive to address this urgent need. By analyzing P-SYN levels in cutaneous nerve fibers, this test offers an objective way to identify the underlying pathology of synucleinopathies, which may lead to better diagnostic and care options for patients.
The study, which recruited 428 adults between the ages of 40 and 99, revealed promising results. The commercially available Syn-One test used in the analysis detected P-SYN in 95.5% of participants overall. These included individuals diagnosed with PD, DLB, MSA, or FAP, as well as a control group without symptoms suggestive of synucleinopathy.
The specific results show a high sensitivity of the test, detecting P-SYN in 92.7% of cases of PD, 98.2% of MSA, 96% of DLB and 100% of PAF. However, some false positives were also observed in the control group, suggesting the need for further research to fully understand the scope and accuracy of the test in different populations.
Although the researchers point out certain limitations, such as the lack of autopsy confirmation of diagnoses and the absence of genetic testing in the participants, The potential of this skin biopsy test to revolutionize the diagnosis and management of synucleinopathies is undeniable according to its authors.
What we should know about degenerative disorders
Neurodegenerative disorders encompass a wide range of diseases that affect the functioning of the central and peripheral nervous system, and between They include Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA)..
PD is a chronic, progressive disease that primarily affects movement, causing tremors, muscle stiffness, and balance problems. As it progresses, it can cause difficulty walking, talking, and performing everyday tasks.
In contrast, DLB is a form of dementia that shares symptoms with Alzheimer’s disease, such as memory loss and cognitive decline, but is also characterized by mood changes, visual hallucinations, and fluctuations in attention and alertness.
MSA is a less common but equally devastating disease, characterized by the progressive degeneration of specific areas of the brain and autonomic nervous system.
While current treatments for these disorders are primarily palliative and not curative, advances in understanding the underlying mechanisms and in the identification of biomarkers such as alpha-synuclein may open new doors for more effective interventions.
Keep reading:
- A mother gives birth to her fifth child in the middle of the ocean
- Electronic cigarette users have DNA changes just like traditional smokers
- Salmon Might Not Be the Healthiest Fish to Eat: What Scientists Say